Gw6471

Manufactured by Selleck Chemicals

Sourced in United States, China

GW6471 is a lab equipment product that serves as a peroxisome proliferator-activated receptor alpha (PPARα) antagonist. It is used in research applications to study the role of PPARα in various biological processes.

Automatically generated - may contain errors

Lab products found in correlation

Cisplatin, by MedChemExpress (1 mentions) Wy 14643, by Selleck Chemicals (1 mentions) Cycloheximide (chx), by Selleck Chemicals (1 mentions) Doxycycline, by Merck Group (1 mentions) Etomoxir, by Selleck Chemicals (1 mentions) Lipidspot 488, by Biotium (1 mentions) Sytox green nucleic acid stain, by Thermo Fisher Scientific (1 mentions) Dialyzed fbs, by Thermo Fisher Scientific (1 mentions) Pim447, by Selleck Chemicals (1 mentions) Lipidspot 610, by Biotium (1 mentions) Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (1 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Effectene transfection reagent, by Qiagen (1 mentions) Jnk in 8, by Selleck Chemicals (1 mentions) Sp 100030, by Bio-Techne (1 mentions) Gsk3787, by Selleck Chemicals (1 mentions) Sb203580, by InvivoGen (1 mentions) Prooxc system, by Biospherix (1 mentions)

7 protocols using gw6471

Regulation of Cardiomyocyte and Intestinal Cell Metabolism

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mouse atrial cardiomyocytes (HL‐1 cells) and human intestinal epithelial cells (Caco‐2 cells) were purchased from BNCC (Henan, China) and cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C with 5% CO₂. Mouse HL‐1 cells treated with or without palmitic acid (PA; 200 μM; Sigma–Aldrich, St. Louis, MO), FGF19 (100 ng/mL; Proteintech) and PPARα inhibitor (10 μM) (GW6471, Selleck Chemicals) for 24 h. Human Caco‐2 cells were stimulated with or without LCA (100 μM) (MedchemExpress) and UDCA (100 μM; MedchemExpress) for 24 h. The cellular lysates and human Caco‐2 cell culture supernatant were then collected for subsequent experiments.

Zuo K., Fang C., Gao Y., Fu Y., Wang H., Li J., Zhong J., Yang X, & Xu L. (2023). Suppression of the gut microbiota–bile acid–FGF19 axis in patients with atrial fibrillation. Cell Proliferation, 56(11), e13488.

+ Open protocol

+ Expand

Oroxylin A and Cisplatin Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

Oroxylin A (OA) and Cisplatin were obtained from MedChemExpress (MCE, Monmouth Junction, NJ, United States). GW6471 (PPARα antagonist) and WY-14643 (PPARα agonist) were bought from Selleckchem (Houston, TX, United States).

Yao M., Qin S., Xiong J., Xin W., Guan X., Gong S., Chen J., Liu Y., Zhang B., Zhao J, & Huang Y. (2022). Oroxylin A ameliorates AKI-to-CKD transition through maintaining PPARα-BNIP3 signaling-mediated mitochondrial homeostasis. Frontiers in Pharmacology, 13, 935937.

+ Open protocol

+ Expand

Multiparametric Lipid Imaging Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following chemicals were used at the indicated concentrations: 20, 50, and 100 ng/ml Doxycycline (Sigma-Aldrich, D5207), 50 nM CHIR (Selleckchem, S2745), 3 µM PIM447 (Selleckchem, S7985), 4 µM GW6471 (Selleckchem, S2798), 100 µM Etomoxir (Selleckchem, S8244), 20 µg/ml cycloheximide (Selleckchem, S7418), 1:1000 LipidSpot488 (Biotium, 70065) or LipidSpot610 (Biotium, 70069), 167 nM SyTOX Green Nucleic Acid Stain (Fisher Scientific, S7020), 25 mM Glucose (Thermo Scientific, A24940-01), 10% Dialyzed FBS (Gibco, A33820-01).

Chauhan S.S., Casillas A.L., Vizzerra A.D., Liou H., Clements A.N., Flores C.E., Prevost C.T., Kashatus D.F., Snider A.J., Snider J.M, & Warfel N.A. (2023). PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer. Oncogene, 43(6), 406-419.

+ Open protocol

+ Expand

Saussurea involucrata Polysaccharide Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Saussurea involucrata polysaccharide was provided by Infinitus Co., Ltd. (Guangzhou, China). PPAR-α inhibitor (GW6471) was purchased from Selleck (Shanghai, China).

Wang L., Yang K., Jing R., Zhao W., Guo K., Hu Z., Liu G., Xu N., Zhao J., Lin L, & Gao S. (2023). Protective effect of Saussurea involucrata polysaccharide against skin dryness induced by ultraviolet radiation. Frontiers in Pharmacology, 14, 1089537.

+ Open protocol

+ Expand

Huh-7 Cell Culture and Transfection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Huh-7 cells were cultured in DMEM (Gibco) supplemented with 10% FBS (Gibco) at 37°C in a humidified atmosphere with 5% CO₂ and transfected with plasmids using Effectene Transfection Reagent (QIAGEN) according to the manufacturer's protocols. In some experiments, Huh-7 cells were incubated with 20 μM MG132 (MCE, HY-13259) or 10 μM GW6471 (Selleck, S2798) for 24 h or 48 h, respectively, and subjected to western blot analysis.

Deng Y., Han X., Chen H., Zhao C., Chen Y., Zhou J., de The H., Zhu J, & Yuan H. (2023). Ypel5 regulates liver development and function in zebrafish. Journal of Molecular Cell Biology, 15(3), mjad019.

+ Open protocol

+ Expand

Investigating LPA-induced signaling in BMDCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

BMDCs were independently pretreated for 1 hour with the p38 MAPK inhibitor SB203580 (10 μM; Invivogen Cat# tlrl-sb20), the PPAR alpha antagonist GW6471 (50 μM; Selleck Chemical Cat# S2798), the PPAR delta antagonist GSK3787 (10 μM; Selleck Chemical Cat# S8025), the CREB inhibitor 666–15 (10 μM; MedChem Express, Cat# HY-128686); the JNK inhibitor JNK-IN-8 (10 μM; Selleck Chemical Cat# S4901); the NF-κB inhibitor BAY 11–7821 (50 μM; MedChem Express Cat# HY-13453), or the NF-κB/AP1 dual inhibitor SP 100030 (5 μM; Tocris Cat# 5309) and then stimulated with LPA (100 μM) for 2 hours. Expression of Ptgs2 was determined by RT-qPCR. For in vitro assessment of EP4 signaling, BMDCs were pretreated for 1 hour with the EP4 antagonist PGN 1531 (5 μM; Tocris Cat#5327) and then stimulated with LPA (100 μM) and LPS (100 ng/ml) for 4 hours. Expression of type-I ISGs was subsequently quantified by RT-qPCR.

Chae C.S., Sandoval T.A., Hwang S.M., Park E.S., Giovanelli P., Awasthi D., Salvagno C., Emmanuelli A., Tan C., Chaudhary V., Casado J., Kossenkov A.V., Song M., Barrat F.J., Holcomb K., Romero-Sandoval E.A., Zamarin D., Pépin D., D’Andrea A.D., Färkkilä A, & Cubillos-Ruiz J.R. (2022). Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I Interferon Responses in Ovarian Cancer. Cancer discovery, 12(8), 1904-1921.

+ Open protocol

+ Expand

Modeling Ischemia-Reperfusion Injury in ARPE-19 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Based on a previous study, we used oxygen–glucose deprivation/reoxygenation (OGD/R) to study IR injury in ARPE‐19 cells.¹² For the induction of OGD, cells were washed with PBS, switched to DMEM without glucose and serum and placed in 0.2% O₂ hypoxia chamber controlled by a ProOxC system balanced with 5% CO₂/95% N₂ (Biospherix) for 48 h at 37°C. After the end of OGD, cells were resupplied with glucose‐containing medium and reoxygenated to a normoxic incubator under 5% CO₂/95% air for 24 h. The control cells were maintained with growth medium and normoxia at 37°C for 72 h. Cells were treated with 2.5–10 μM GW6471 (PPAR‐α antagonist, Selleckchem) to investigate the underlying mechanism during ODG/R.

Sun T., Huang K., Niu K., Lin C., Liu W., Yeh C., Kuo S, & Chang C. (2023). Hyperbaric oxygen therapy suppresses hypoxia and reoxygenation injury to retinal pigment epithelial cells through activating peroxisome proliferator activator receptor‐alpha signalling. Journal of Cellular and Molecular Medicine, 27(20), 3189-3201.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!